Stockreport

Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

Iterum Therapeutics plc - Ordinary Share  (ITRM) 
Last iterum therapeutics plc - ordinary share earnings: 11/12 04:30 pm Check Earnings Report
PDF Phase 3 REASSURE Trial Met Primary Endpoint of Non-Inferiority to Augmentin®; Demonstrated Statistical SuperiorityRe-submission of NDA to FDA Expected in Q2 2024Potentia [Read more]